Stock events for Theriva Biologics, Inc. (TOVX)
Theriva Biologics' stock has experienced significant fluctuations and a substantial decline over the past six months. Key events impacting the stock include unusual trading activity on October 24, 2025, a 5-day losing streak as of October 23, 2025, a drop in short interest in September 2025, the Q3 2025 operational highlights and financial results reported on November 12, 2025, positive scientific advice from the EMA regarding the design of a Phase 3 trial for VCN-01 on December 29, 2025, the licensing of SYN-020 to Rasayana Therapeutics on February 18, 2026, and an upcoming presentation of Phase 1 clinical outcome and safety data for intravitreal VCN-01 on February 7, 2026.
Demand Seasonality affecting Theriva Biologics, Inc.’s stock price
Seasonality analysis for Theriva Biologics, Inc. reveals recurring patterns in asset prices over a calendar year. January offers the highest probability of positive returns, while March may not be an ideal month to invest in TOVX.
Overview of Theriva Biologics, Inc.’s business
Theriva Biologics, Inc. is a clinical-stage biotechnology company in Rockville, Maryland, focused on developing biologic therapies for unmet medical needs within the Healthcare sector, specifically in the Pharmaceutical Products and Biotechnology industries. The company's major product candidates include VCN-01, an oncolytic adenovirus in clinical trials for various cancers; VCN-11 and VCN-12, oncolytic adenoviruses in preclinical development; SYN-004 (ribaxamase), designed to degrade certain intravenous beta-lactam antibiotics; SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase; SYN-006, a clinical-stage product aimed at preventing aGVHD and infection by carbapenem-resistant enterococci; and SYN-007, a clinical-stage product for preventing antibiotic-associated diarrhea with oral ß-lactam antibiotics.
TOVX’s Geographic footprint
Theriva Biologics, Inc. is headquartered in Rockville, Maryland, and primarily develops therapeutics for the U.S. market. The company has a subsidiary, Theriva Biologics, S.L., involved in developing its oncolytic adenovirus platform, and collaborates with institutions in both the United States and Spain.
TOVX Corporate Image Assessment
Theriva Biologics has received a "Hold" consensus rating from Wall Street research analysts. MarketBeat indicates that Theriva Biologics scored higher than 2% of companies evaluated, and TradeSmith's Health Indicator has placed TOVX in the "Red zone" for over two months, signaling unhealthy financial health. However, the company has also had positive developments, such as reporting positive topline results from its VIRAGE Phase 2b trial, presenting Phase 1 safety and clinical outcome data for VCN-01, receiving positive scientific advice from the European Medicines Agency, and licensing SYN-020 to Rasayana Therapeutics.
Ownership
Theriva Biologics, Inc. has a mixed ownership structure comprising institutional, insider, and retail investors. Institutional investors hold approximately 0.26% to 6.17% of the company's stock, with major shareholders including Vanguard Group Inc and UBS Group AG. Individual/insider ownership is led by Steven A. Shallcross, owning 0.74% of the company. Retail investors hold a significant portion, approximately 95.42% to 98.86% of the company's stock.
